TEVJF — TEVA PHARMACEUTICAL INDUSTRIES LTD

NYSE · Health Care · Pharmaceuticals · CIK 818686 · Israel
Last close
$28.40
Market Cap
$33.07B
52W High
$37.00
52W Low
$28.40
ADV30
10
Next earnings
2026-07-29
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026
Mar 2026 3,981,000,000 1,972,000,000 759,000,000 369,000,000 40,040,000,000 3,741,000,000 31,808,000,000
Dec 2025 4,711,000,000 2,656,000,000 1,269,000,000 480,000,000 40,748,000,000 3,556,000,000 32,834,000,000
Sep 2025 4,480,000,000 2,304,000,000 1,075,000,000 433,000,000 39,856,000,000 2,203,000,000 32,602,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,714,000,000
Investing CF
$765,000,000
Financing CF
$-394,000,000
CapEx
$-542,000,000
Dividends Paid
Buybacks
EPS Diluted TTM
$1.14
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-13,394,000,000
Inventory
$3,176,000,000
Receivables
$3,393,000,000
ST Investments
EBIT TTM
$2,271,000,000
Pretax Income TTM
$1,366,000,000
Interest Exp TTM
$905,000,000
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$17,315,000,320
EBITDA
$4,268,000,000
Free Cash Flow
$2,219,875,072
Enterprise Value
$46,337,409,024
Total Cash
$3,655,000,064
Total Debt
$16,894,000,128
Shares Out
1,164,426,972
Trailing EPS
$0.60
Book Value
$6.65
ROE
9.7%
ROA
5.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 17,257,000,000 3,952,000,000 1,410,000,000 40,748,000,000 32,834,000,000 1,649,000,000
Dec 2024 16,544,000,000 3,364,000,000 -1,639,000,000 39,326,000,000 33,606,000,000 1,247,000,000
Dec 2023 15,845,000,000 3,194,000,000 -559,000,000 43,479,000,000 35,353,000,000 1,368,000,000
Dec 2022 14,925,000,000 2,690,000,000 -2,446,000,000 44,011,000,000 35,413,000,000 1,590,000,000

Peers — same industry

TickerNameMarket CapLastDaily %
ZTS Zoetis Inc. $32.40B $77.29
ONC BeOne Medicines Ltd. $29.99B $316.01
ALNY ALNYLAM PHARMACEUTICALS, INC. $27.44B $205.52
BEIGF BeOne Medicines Ltd. $27.08B $21.95
TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD $40.77B $35.01

News headlines (Yahoo Finance, 1h cache)

Teva (TEVA) Lifts UZEDY Outlook After Record Sales And New FDA Progress
2026-07-30 17:07 · Yahoo
Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises
2026-07-30 16:21 · Yahoo
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | Delve
2026-07-30 14:31 · Yahoo
Is Teva Pharmaceutical Industries (TEVA) A Bargain After Results And Higher Revenue Guidance?
2026-07-30 12:08 · Yahoo
Teva Pharmaceutical Industries Q2 Earnings Call Highlights
2026-07-30 12:03 · Yahoo
Is Teva (TEVA) Trading Profit for Future Potential With Its Branded‑Drug Pivot?
2026-07-30 11:10 · Yahoo
Teva CEO on Drug Pipeline, Direct Listing on NYSE
2026-07-29 23:58 · Yahoo
Teva Stock Rises After Earnings as Revenue Guidance Exceeds Expectations
2026-07-29 19:10 · Yahoo
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Highlights: Strong Innovative ...
2026-07-29 19:03 · Yahoo
Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views
2026-07-29 17:20 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.